title: Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
abstract: In this review, the functional interactions between serotonin (5-HT) and dopamine (DA) neuronal systems are discussed with the focus on microdialysis studies in the rodent brain (mainly rats). 5-HT by itself is involved both directly and indirectly via actions on complex neuronal circuitry, in the regulation of DA release through multiple 5-HT receptors, playing a critical role in the development of normal and abnormal behaviours. Recent evidence suggests that dysfunction of dopaminergic and serotoninergic neurotransmitter systems contributes to various disorders including depression, schizophrenia, Parkinson's disease and drug abuse. Here we summarize recent neurochemical works that have extensively explored the role of 5-HT receptors in the control of DA central systems in both basal and drug-induced conditions, using in vivo microdialytic techniques. Several 5-HT receptor subtypes, including the 5-HT(1A), 5-HT(1B), 5-HT(2A), 5-HT(3) and 5-HT(4) receptors, act to facilitate DA release, while the 5-HT(2C) receptor mediates an inhibitory effect of 5-HT on DA release. Taken together, neurochemical approaches using microdialysis can not only contribute to clarification of the physiological role of the serotonergic neuronal systems but may also be a powerful pharmacological approach for the development of therapeutic strategies to the treatment of depression, schizophrenia, Parkinson's disease and drug abuse.
authors.affiliation: Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro, Chieti, Italy. vdimatteo@negrisud.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Matteo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Giovanni
authors.forename: Massimo
authors.initials: M
authors.lastname: Pierucci
authors.forename: Ennio
authors.initials: E
authors.lastname: Esposito
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000033:anatomy & histology / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000378:metabolism; D018492:Dopamine Antagonists / Q000378:metabolism; D006801:Humans; D013287:Illicit Drugs / Q000378:metabolism; D001523:Mental Disorders / Q000503:physiopathology; D008636:Mesencephalon / Q000033:anatomy & histology / Q000378:metabolism; D017551:Microdialysis / Q000295:instrumentation / Q000379:methods*; D009434:Neural Pathways / Q000033:anatomy & histology / Q000502:physiology; D011985:Receptors, Serotonin / Q000145:classification / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000378:metabolism; D013378:Substantia Nigra / Q000033:anatomy & histology / Q000378:metabolism; D009435:Synaptic Transmission / Q000502:physiology
chemical_list: D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D013287:Illicit Drugs; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D004298:Dopamine